Free Webcast of the Pre-Meeting Symposium at the 2011 Annual Meeting of
The North American Menopause Society (NAMS)
Release Date: October 25, 2011
Expiration Date: October 25, 2012
Estimated Time of Completion: 4 hours
This free archived webcast captures the Pre-Meeting Symposium held in advance of the 22nd Annual Meeting of The North American Menopause Society on September 21, 2011. This half-day symposium consisted of five expert lectures on timely clinical issues surrounding the use of hormone therapy (HT) in peri- and postmenopausal women, two panel sessions in which the speakers answered audience questions, and a panel discussion on the management of challenging cases.
This activity has been designed to meet the educational needs of physicians, nurses, nurse practitioners, physician assistants, pharmacists, and other healthcare providers who treat or counsel women at midlife and beyond.
At the conclusion of this activity, participants should be able to:
- Explain how recent findings from the Women’s Health Initiative and other studies fill knowledge gaps about the “critical window” hypothesis, differences among HT formulations, and the role of risk stratification in individualizing decisions about HT
- Describe the role of estrogen in menopause-associated mood disturbances and apply evidence-based strategies (hormonal and nonhormonal) to manage these disturbances
- Recognize and explain to patients the impact of route of administration of systemic estrogen (oral vs nonoral) on the overall risk-to-benefit ratio of HT
- Choose among available forms of progestogen therapy to optimally balance quality-of-life issues, cardiovascular effects, and endometrial protection for individual patients
- Summarize comparative safety and efficacy data for FDA-approved vs. custom-compounded bioidentical HT preparations, and counsel patients on concerns and risks surrounding custom-compounded preparations
- Outline a plan for managing hot flashes and other symptoms of menopause in women who present with complicating factors such as a history of breast cancer or deep venous thrombosis
The North American Menopause Society (NAMS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
NAMS designates this enduring material for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nonphysician healthcare professionals who complete this activity will be issued a certificate of participation.
|
|
Associate Professor of Obstetrics, Gynecology & Reproductive Biology
Harvard Medical School
Director, Menopause Program
Vincent Obstetrics & Gynecology Service
Massachusetts General Hospital
Boston, MA |
|
|
Clinical Professor, Department of Obstetrics, Gynecology & Reproductive Sciences
University of California, San Francisco
Berkeley, CA |
|
|
Chief, Division of Preventive Medicine
Brigham & Women’s Hospital
Professor of Medicine and the Michael & Lee Bell Professor of Women’s Health
Harvard Medical School
Boston, MA |
|
|
Consultant Gynaecologist, Subspecialist in Reproductive Medicine & Surgery
Queen Charlotte’s & Chelsea Hospital
Director, West London Menopause & PMS Centre
Queen Charlotte’s & Chelsea Hospital and Chelsea & Westminster Hospital
London, United Kingdom |
|
|
Professor of Obstetrics & Gynecology
Vice Chair for Academic Affairs
Director, Midlife Health
University of Virginia Health Sciences Center
Charlottesville, VA |
|
|
Clinical Professor, Department of Obstetrics & Gynecology
The George Washington University School of Medicine
Medical Director, Women’s Health & Research Consultants
Washington, DC |
|
|
Professor of Psychiatry & Behavioural Neurosciences and Obstetrics & Gynecology
Academic Head, Mood Disorders Division
Director, Women’s Health Concerns Clinic
McMaster University
Hamilton, ON, Canada |
This activity has been planned and implemented in accordance with the ACCME’s Essential Areas and Elements, including its Standards for Commercial Support. As a CME provider, NAMS is committed to ensuring independence, balance, and objectivity in its educational activities and has implemented policies and procedures for collecting disclosure information from all faculty and planners involved. NAMS is committed to resolving any conflict, making certain that the activity’s content is aligned with the interests of the public, and is dedicated to implementing safeguards against bias when content is relevant to a commercial interest.
This activity’s faculty and planners reported the following relationships that, in the context of their contributions here, could be perceived as a potential conflict of interest:
Dr. Kagan reports: Advisory Board—Amgen, Bionovo, Depomed, Foundation for Osteoporosis Research and Education/American Bone Health, Merck, Novo Nordisk, Own the Bone Advisory Board of the American Orthopedic Association, Pfizer, Shionogi; Grant/Research Support—Bionovo, Biosante, Boehringer Ingelheim, Depomed, Pfizer; Speakers Bureau—Amgen, Novo
Nordisk, Novogyne
Dr. Manson reports no relevant financial relationships
Dr. Panay reports: Advisory Board—Bayer, Novo Nordisk, Se-cure; Speaking Fee/Stipend—Bayer, Novo Nordisk, Se-cure
Dr. Pinkerton reports: Advisory Board—Amgen, Depomed, Endoceutics, Novo Nordisk, Teva; Consultant—Amgen, Depomed, Novo Nordisk, Pfizer, Teva; Grant/Research Support—Depomed, Endoceutics, Pfizer
Dr. Shifren (activity director and moderator) reports: Advisory Board—New England Research Institutes; Grant/Research Support—Boehringer Ingelheim
Dr. Simon reports: Consultant—Abbott, Agile, Amgen, Ascend, Azur, BioSante, Boehringer Ingelheim, Depomed, Fabre-Kramer, Laboratoire HRA, Meditrina, Merck, Merrion, NDA Partners, Novo Nordisk, Novogyne, Pfizer, Shionogi, Slate, Teva, Trovis, Warner Chilcott, Watson; Grant/Research Support—BioSante, Boehringer Ingelheim, Endoceutics, Novo Nordisk, Novogyne, Teva; Speakers Bureau—Amgen, Ascend, Bayer, Boehringer Ingelheim, KV, Merck, Novartis, Novo Nordisk, Novogyne, Teva, Warner Chilcott
Dr. Soares reports: Advisory Board—AstraZeneca, Canadian Institutes of Health Research, Eli Lilly, Lundbeck, Narsad, Pfizer; Consultant—AstraZeneca, Lundbeck, Pfizer; Grant/Research Support—Canadian Institutes of Health Research, Eli Lilly, Narsad, Pfizer; Speakers Bureau—AstraZeneca, Lundbeck, Pfizer
All NAMS staff who could have any influence on the content of this activity reported having no relevant financial relationships to disclose.
This CME activity is supported by grant funding from Abbott Laboratories, Pfizer Inc., Teva Women’s Health, Upsher-Smith Laboratories, Inc., and Warner Chilcott.
There are no fees for participating in this online educational activity. For information on the applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
NOTE: Persons who claimed credit for attending the live September 21, 2011, symposium on which this webcast was based may not claim credit for this webcast activity as well.
To successfully earn credit, participants must follow these steps:
- Read the preceding information on this page
- Click “Begin Activity” below and view the webcast content on the page that follows. You may view the entire symposium or proceed through its individual video segments, most of which are 30 minutes long; just be sure to claim only the credit commensurate with your degree of participation.
- After viewing the webcast content, click “Proceed to Post-Test & Evaluation” at the bottom of the webcast page
- You will be linked to a PDF form containing a 10-question post-test and activity evaluation. Print this form, fill it out completely, and return the completed form to NAMS by fax (440-442-2660), by mail (see form for address), or by emailing a scan of the form to nams@menopause.org. If you achieve a score of 70% or better on the post-test, NAMS will issue your credit certificate by mail within 30 days. (If you score below 70% on the post-test, you will be given one opportunity to repeat the activity and resubmit your post-test and evaluation.)
To view this activity, users will need:
1) A computer or device with an Internet connection
2) Either of the following:
- With Microsoft Silverlight 4 installed, any of the following: Internet Explorer 7 or higher, Safari 3 or higher (Mac only), Firefox 3 or higher, or Chrome 4 or higher
- Without Microsoft Silverlight 4 installed, any of the following: Internet Explorer 9, Safari 4 or higher (Mac, PC, or iPad), Firefox 3.6 or higher, or Chrome 4 or higher
To verify your Microsoft Silverlight 4 installation status, visit http://www.microsoft.com/getsilverlight/get-started/install/default.aspx. Users will be prompted if they do not meet the above software requirements.
3) Adobe Reader
For technical assistance or for questions regarding the content of this activity, contact nams@menopause.org.
The contents of this activity are © 2011 The North American Menopause Society. All rights reserved. |